Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults

Vaccine

Volumn 31, Issue 47, 2013, Pages 5531-5536

  Verdijk, Pauline ^a   Rots, Nynke Y ^b   van Oijen, Monique G C T ^a   Oberste, M Steven ^c   Boog, Claire J ^a   Okayasu, Hiromasa ^d   Sutter, Roland W ^d   Bakker, Wilfried A M ^a  

^a Institute for Translational Vaccinology   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adjuvant; Aluminum hydroxide; Immunogenicity; Inactivated poliovirus vaccine; Phase I trial; Sabin strains; Safety

Indexed keywords

ALUMINUM HYDROXIDE; POLIOMYELITIS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MUSCLE RIGIDITY; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VOMITING;

ADJUVANT; ALUMINUM HYDROXIDE; CIPV; CONVENTIONAL IPV; D-ANTIGEN UNITS; DU; IMMUNOGENICITY; INACTIVATED POLIOVIRUS VACCINE; IPV; PHASE I TRIAL; SABIN STRAINS; SAFETY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; YOUNG ADULT;

EID: 84886770888     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.021     Document Type: Article

References (18)

1. Global eradication of poliomyelitis by the year 2000. Forty-first World Health Assembly, WHA41.281988.
2. Salk J.E. A concept of the mechanism of immunity for preventing paralysis in poliomyelitis. Ann N Y Acad Sci 1955, 61:1023-1036. [Discussion, 36-8].
3. Salk J.E. Vaccination against paralytic poliomyelitis performance and prospects. Am J Public Health Nations Health 1955, 45:575-596.
4. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vacc 2009, 8:899-905.
5. Sabin A.B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985, 151:420-436.
6. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vacc 2009, 8:5-8.
7. Grassly N.C., Fraser C., Wenger J., Deshpande J.M., Sutter R.W., Heymann D.L., et al. New strategies for the elimination of polio from India. Science 2006, 314:1150-1153.
8. Agol V.I. Vaccine-derived polioviruses. Biologicals 2006, 34:103-108.
9. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
10. Meeting Meeting of the strategic advisory group of experts on immunization, november 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2013, 88:1-16.
11. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652.
12. Chumakov K., Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008, 47:1587-1592.
13. Polio Polio vaccines and polio immunization in the pre-eradication era: WHO position paper - recommendations. Vaccine 2010, 28:6943-6944.
14. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28:3778-3783.
15. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34:155-158.
16. Verdijk P., Rots N.Y., Bakker W.A. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vacc 2011, 10:635-644.
17. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001, 105:163-169.
18. Okada K., Miyazaki C., Kino Y., Ozaki T., Hirose M., Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from sabin strains (DTaP-sIPV). J Infect Dis 208, 2013, 275-283.